Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Wren Capital
Deal Size : $5.0 million
Deal Type : Financing
Details : The company will use the net proceeds to develop its first-in-class therapeutic pipeline which targets mitochondria dysfunction linked to the progression of rare diseases such as the neuromuscular disorder Duchenne muscular dystrophy, Huntington’s dise...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Wren Capital
Deal Size : $5.0 million
Deal Type : Financing
Reset All
